Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model

Journal of Materials Science: Materials in Medicine

Volumn 24, Issue 1, 2013, Pages 115-127

  Lewis, Andrew L ^a   Holden, Rachel R ^a   Chung, S Ting ^a   Czuczman, Peter ^a   Kuchel, Timothy ^b   Finnie, John ^b   Porter, Susan ^b   Foster, David ^b  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

^b Institute of Medicine and Veternary Science   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL PARAMETERS; BLOOD SAMPLES; CLINICAL EFFECTS; COLORECTAL CANCER; COMBINED TREATMENT; DRUG CLEARANCE; EMBOLIZATION; EXTENDED RELEASE; HAEMATOLOGY; HIGH DOSE; INTRAVENOUS ADMINISTRATION; IRINOTECAN; PHARMACOKINETIC ANALYSIS; PHARMACOKINETIC PROFILES; PHARMACOKINETIC STUDIES; PLASMA LEVELS; PORCINE MODELS;

ANIMALS; BIOCHEMISTRY; PLASMAS;

PHARMACOKINETICS;

CALCIUM; CALCIUM ION; DBL; FIRTECAN; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; PHOSPHATE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY DEVICE; DRUG ELUTING BEAD; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; EXPERIMENTAL PIG; FEASIBILITY STUDY; FEMALE; FEMORAL ARTERY; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; KUPFFER CELL; LEUKOCYTE COUNT; LIMIT OF QUANTITATION; LIVER BLOOD FLOW; LIVER CELL; LIVER FIBROSIS; LYMPH NODE; MAXIMUM PLASMA CONCENTRATION; MONONUCLEAR CELL; MONOTHERAPY; MUSCLE HYPERTROPHY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; THROMBOCYTE COUNT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEASIBILITY STUDIES; LIVER; MODELS, ANIMAL; SWINE;

ANIMALIA; SUIDAE; SUS;

EID: 84872424918     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-012-4768-2     Document Type: Article

References (42)

1. Graeven U, et al. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie. 2007;30(4):169-74.
2. Vogl TJ, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17(4):1025-34.
3. Llovet JM, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734-9.
4. Lo CM, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164-71.
5. Taniai N, et al. Good embolization response for colorectal liver metastases with hypervascularity. Hepatogastroenterology. 2002;49(48):1531-4.
6. Lang EK, Brown CL Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology. 1993;189(2):417-22.
7. Sanz-Altamira PM, et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997;40(7):770-5.
8. Vogl TJ, et al. Liver metastases of colorectal carcinoma: prospective study on the use of transarterial chemoembolization (TACE). J Clin Oncol. 2007;25(18S):4062.
9. Gonzalez MV, et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in vitro:in vivo correlation. J Mater Sci Mater Med. 2007;19:767-75.
10. Lewis AL, et al. Doxorubicin eluting beads: 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18(9):1691-9.
11. Lewis AL, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(2 Pt 1):335-42.
12. Kettenbach J, et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Interv Radiol. 2008;31(3):468-76.
13. Malagari K, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging. 2007;33(5):512-9.
14. Malagari K, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol. 2008;31:269-80.
15. Varela M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474-81.
16. Aliberti C, et al. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Interv Radiol. 2008;31(5):883-8.
17. de Baere T, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol. 2008;19(6):855-61.
18. Tang Y, et al. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release. 2006;116(2):e55-6.
19. Small SA, Lewis AL, Antonijevic MD. Topotecan uptake and elution by drug eluting beads. J Pharm Pharmacol. 2008;57(Suppl 1):A-24.
20. Forster RE, et al. Comparison of DC bead-irinotecan and DC bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. J Mater Sci Mater Med. 2010;21(9):2683-90.
21. Taylor RR, et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci. 2007;30(1):7-14.
22. Rao PP, et al. Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. Cardiovasc Interv Radiol. 2012. [Epub ahead of print].
23. Eyol E, et al. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis. 2008;25(3):273-82.
24. Aliberti C, et al. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006;26(5B):3793-5.
25. Fiorentini G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo. 2007;21:1085-92.
26. Martin RC, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192-8.
27. Martin RC, et al. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. 2009;2009:539-795.
28. Fiorentini G, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387-95.
29. Martin RC 2, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg. 2012;16(8):1531-8.
30. Kelley KW, et al. Body surface area of female swine. J Anim Sci. 1973;36(5):927-30.
31. Siu LL, Rowinsky EK. A risk-benefit assessment of irinotecan in solid tumours. Drug Saf. 1998;18(6):395-417.
32. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476-87.
33. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328-35.
34. Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-45.
35. Buijs M, et al. Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization: single-center experience. Radiology. 2008;249(1):346-54.
36. Yoshikawa C, et al. Changes in serum enzyme activity after transcatheter arterial embolization for hepatic neoplasm. Clin Biochem. 1987;20(6):435-40.
37. Tang Y, et al. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases. J Control Release. 2008;127:70-8.
38. Boxenbaum H. Pharmacokinetic tricks and traps: flip-flop models. J Pharm Pharmaceut Sci. 1998;1(3):90-1.
39. Gerrits CJ, et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer. 1997;76(7):952-62.
40. Abigerges D, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst. 1994;86(6):446-9.
41. Martin RC, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Interv Radiol. 2010;33(5):960-6.
42. Fiorentini G, et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology. 2008;55(88):2077-82.